

Fax completed form to: 1-866-868-0858  
Questions, please call: 1-866-316-6049



## **Important Information About Prescription Drug Coverage**

---

To: \_\_\_\_\_ From: \_\_\_\_\_

Fax: \_\_\_\_\_ Pages: \_\_\_\_\_

Re: Novantrone® (Mitoxantrone): Prior Authorization Request Form: Please respond.

---

- Please complete the attached Novantrone® (Mitoxantrone) Prior Authorization Request Form
- To expedite the review process please complete all requested fields.
- Completed forms should be faxed to: 1-866-868-0858. It is not necessary to fax this cover page.

**Please note:** By signing the attached form you are certifying that the treatment requested is medically necessary. No contraindications are present and precautions have been considered. You will be supervising the patient's treatment. Supporting documentation is available in the patient's record. Signature on this form attests to the fact that the corresponding ICD-9 code has been documented in the patients chart and submitted on a CMS- 1500 form.

### Information about this drug

---

#### Novantrone® (Mitoxantrone)

Patients treated with mitoxantrone should be monitored routinely for cardiac, liver and kidney function abnormalities. Secondary acute myelogenous leukemia (AML) has been reported in multiple sclerosis and cancer patients treated with mitoxantrone.

You can make an expedited request by indicating this at the top of the attached form. If you request an expedited review, and sign the attached form, you certify that applying the 72 hour standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

**Information on the attached form is protected health information and subject to all privacy and security regulations under HIPAA.**

# Prior Authorization Request Form



Fax completed form to 1-866-868-0858 Need help? Call 1-866-316-6049

## Patient Information

Name \_\_\_\_\_  
Member ID \_\_\_\_\_  
Medicare ID \_\_\_\_\_  
Date of birth \_\_\_\_\_ Sex: M / F  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_  
Nursing home resident? YES / NO  
Home care patient? YES / NO

## Prescriber and Pharmacy Information

Name \_\_\_\_\_  
Specialty \_\_\_\_\_  
DEA \_\_\_\_\_  
NPI \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
Pharmacy name \_\_\_\_\_  
NCPDP \_\_\_\_\_  
NPI \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_

## All items below this line are for Physician Use Only

### Information for Requested Drug

Strength: \_\_\_\_\_ Dosage form: \_\_\_\_\_ Qty per 30 days: \_\_\_\_\_ Drug is (circle one): Newly prescribed/Refill  
Directions: \_\_\_\_\_ Diagnosis: \_\_\_\_\_ ICD-9 Code: \_\_\_\_\_

Standard Reviews will be completed in under 72 hours. An expedited review is available if you certify that a standard review timeframe will seriously jeopardize the health of your patient. To request an expedited review, simply indicate this at the top of this page.

### Novantrone® (Mitoxantrone) Criteria

- 1 Please indicate Mitoxantrone's dispensing location:  
 Pharmacy  
 Physician's supply, incident to a physician's service  
 Other \_\_\_\_\_
- 2 Please indicate the patient's diagnosis. Select or specify the correct ICD-9 code. This question must be completed.  
 Acute myeloid leukemia in combination with other approved agents (ICD-9: 205)  
 Multiple sclerosis, secondary progressive, progressive relapsing, or worsening relapsing-remitting, to reduce neurologic disability and/or frequency of clinical relapse (ICD-9: 340)  
 Palliative treatment of prostate cancer, with corticosteroids, for pain related to advanced hormone-refractory prostate cancer (ICD-9: 185)  
 Other(diagnosis and ICD-9): \_\_\_\_\_
- 3 If the diagnosis is multiple sclerosis, has the patient failed to receive a clinically appropriate therapeutic response OR demonstrated intolerance (i.e., allergy, hypersensitivity, adverse effects, development of a contraindication) to Betaseron®, Rebif®, Avonex®, Copaxone® or corticosteroids?  
 Yes  No
- 4 Is the prescribing physician a hematologist/oncologist or has one been consulted?  
 Yes  No
- 5 Will Mitoxantrone be administered in a facility where the patient can be closely monitored for an appropriate period based on health status?  
 Yes  No
- 6 Does the patient have a history of hypersensitivity to Mitoxantrone?  
 Yes  No

Medical justification: (Attach additional page if necessary): \_\_\_\_\_

Prescriber's signature: \_\_\_\_\_ Date: \_\_\_\_\_